Understanding FDA Section 524B: The Regulatory Landscape
The 2023 Omnibus amendments to FDA Section 524B fundamentally reshape how health systems evaluate, procure, and maintain cybersecurity governance for medical devices. Previously, device cybersecurity was addressed through non-binding FDA guidance; Section 524B now creates enforceable regulatory requirements that apply across the device lifecycle—from design through post-market surveillance. For health system Chief Information Security Officers (CISOs) and procurement officers, this transition from guidance to regulation demands immediate action in vendor assessment protocols, contractual language, and ongoing compliance monitoring.
Section 524B requires manufacturers to implement and maintain a cybersecurity program aligned with recognized standards, including NIST Cybersecurity Framework components, secure development practices, and vulnerability management. The regulation explicitly mandates that manufacturers provide health systems with documented evidence of their cybersecurity posture. This creates a new information asymmetry problem: CISOs now must request, evaluate, and validate manufacturer security claims during procurement—a capability that many health systems have not yet operationalized at scale.
Key Cybersecurity Mandates Affecting Procurement
Secure Product Design and Development
Under Section 524B, manufacturers must demonstrate that cybersecurity was embedded throughout the product development lifecycle, not bolted on post-design. This aligns with the NIST Secure Software Development Framework (SSDF) and CIS Critical Control 3.1 (Inventory of Authorized Software). When evaluating devices, procurement teams should request evidence of threat modeling, secure code review practices, and third-party security testing during development. CISOs should require manufacturers to document their software bill of materials (SBOM) and provide it during procurement—a control that directly supports supply chain risk management under NIST CSF Identify and Protect functions.
Health systems must update their vendor questionnaires to include specific questions about development methodologies, version control systems, and whether security was a primary design consideration or an afterthought. This is not merely a compliance checkbox; it fundamentally impacts the risk profile of the device once deployed in your clinical environment.
Vulnerability Management and Disclosure
Section 524B requires manufacturers to establish documented processes for identifying, reporting, and remediating vulnerabilities. The regulation mandates that manufacturers coordinate with health systems on patch deployment timelines, a critical control for clinical environments where downtime can directly impact patient safety. Procurement contracts must now include explicit language requiring manufacturers to:
Provide security patches and updates within defined timeframes aligned with severity (following CVSS v3.1 scoring or equivalent);
Maintain a coordinated disclosure process compliant with CISA's guidance on vulnerability reporting;
Guarantee security support for a defined product lifecycle period, not indefinitely.
This requirement intersects directly with HIPAA Security Rule §164.308(a)(5) (security incident procedures) and HITRUST CSF 06.1 (Incident Management). CISOs should establish device-specific vulnerability management workflows that integrate manufacturer patch notifications into existing change management and security testing protocols.
Documentation, Transparency, and Evidence
Perhaps the most operationally significant mandate is the requirement that manufacturers provide health systems with documented evidence of their cybersecurity program. Section 524B does not require manufacturers to share proprietary source code, but it does mandate transparency about security controls, testing methods, and residual risks. Health systems should now expect to receive during procurement:
A cybersecurity summary document describing the manufacturer's program maturity;
Evidence of third-party security assessments or certifications (e.g., ISO 27001, IEC 62304);
A device-specific threat model or risk assessment summary;
A software composition report identifying third-party components and known vulnerabilities;
Post-market cybersecurity surveillance procedures.
Procurement and Vendor Management Integration
Updating Procurement Workflows
CISOs should immediately work with procurement teams to establish a medical device cybersecurity assessment process aligned with NIST CSF Govern, Manage, and Inform functions. This process should include a standardized vendor cybersecurity questionnaire (consider adapting Shared Services Partner healthcare vendor assessment templates), a technical security review stage, and contractual requirements that lock manufacturers into Section 524B compliance obligations.
Procurement teams must understand that cost-lowest-bid approaches are no longer acceptable when cybersecurity risk is material. A FAIR (Factor Analysis of Information Risk) analysis can quantify the risk premium associated with weaker device security, translating security requirements into business value for procurement stakeholders who may be unfamiliar with cybersecurity language.
Contractual Requirements and SLAs
Update device procurement contracts to explicitly reference Section 524B compliance as a material requirement. Include specific service-level agreements (SLAs) for security patch deployment, vulnerability disclosure timelines, and end-of-life support. Require manufacturers to notify your organization within 48 hours of discovering a vulnerability affecting your deployed devices, and establish clear escalation procedures for critical vulnerabilities that could impact patient safety or data confidentiality.
Compliance Monitoring and Documentation
Section 524B compliance is not a one-time procurement activity. Health systems must establish ongoing compliance monitoring, including annual vendor security questionnaire updates, tracking of security patches and updates, and periodic review of manufacturer cybersecurity incident reports. Document all vendor assessments, decisions, and risk acceptance approvals within your governance framework—FDA surveyors reviewing HIPAA Security Rule compliance will expect to see evidence that device cybersecurity was systematically evaluated and monitored.
Conclusion
The 2023 Omnibus amendments to FDA Section 524B represent a maturation of healthcare device security governance. CISOs must now treat device cybersecurity as a material procurement and compliance risk, requiring integration with existing vendor management, risk assessment, and incident response frameworks. Organizations that begin implementing Section 524B-aligned procurement processes today will establish a competitive advantage in vendor relationships, reduce post-deployment security surprises, and build a documented compliance posture that satisfies both FDA and OIG expectations.